Arcadia Biosciences (RKDA) Announces Third Quarter 2025 Financial Results and Business Highlights
Arcadia Biosciences (Nasdaq: RKDA) reported third quarter 2025 results on Nov 7, 2025 showing mixed operating performance and balance sheet activity.
Zola year-to-date revenue rose 26% driven by increased distribution; third-quarter revenues were flat year‑over‑year. Gross profit margins exceeded 30% for the 11th consecutive quarter. Cash declined by $257K to $1.1M. The company recognized a $4.7M credit loss2.7M shares of Above Food Ingredients as partial repayment.
Arcadia Biosciences (Nasdaq: RKDA) ha comunicato i risultati del terzo trimestre 2025 il 7 novembre 2025, evidenziando una performance operativa mista e un’attività di bilancio.
Zola Le entrate dall'inizio dell'anno fino ad oggi sono aumentate del 26% grazie a una maggiore distribuzione; le entrate del terzo trimestre sono rimaste stabili rispetto all'anno precedente. I margini di utile lordo hanno superato il 30% per l’undicesimo trimestre consecutivo. La liquidità è diminuita di $257K a $1.1M. La società ha riconosciuto una perdita su credito di $4.7M relativa a una nota promissoria in essere e ha ricevuto circa 2.7M azioni di Above Food Ingredients come pagamento parziale.
Arcadia Biosciences (Nasdaq: RKDA) informó los resultados del tercer trimestre de 2025 el 7 de noviembre de 2025, mostrando un rendimiento operativo mixto y actividad en el balance.
Zola los ingresos acumulados del año hasta la fecha aumentaron un 26% impulsados por una mayor distribución; los ingresos del tercer trimestre fueron estables interanual. Los márgenes de beneficio bruto superaron el 30% por el undécimo trimestre consecutivo. La liquidez cayó en $257K a $1.1M. La compañía ha reconocido una pérdida por crédito de $4.7M relacionada con una nota promissoria pendiente y recibió aproximadamente 2.7M acciones de Above Food Ingredients como pago parcial.
Arcadia Biosciences (Nasdaq: RKDA)는 2025년 11월 7일에 2025년 3분기 실적을 발표했으며 다양한 영업 실적과 대차대조표 활동을 보여주었습니다.
Zola 연간 누적 매출은 26% 증가했으며 이는 배포 증가에 의해 추진되었고, 3분기 매출은 전년 동기 대비 제자리였습니다. 총이익률은 연속 11번째 분기 30%를 상회했습니다. 현금은 $257K에서 $1.1M로 감소했습니다. 회사는 미지급 약약에 관련된 $4.7M의 신용손실을 인식했으며 부분 상환으로 약 2.7M주의 Above Food Ingredients 주식을 받았습니다.
Arcadia Biosciences (Nasdaq: RKDA) a publié les résultats du troisième trimestre 2025 le 7 novembre 2025, montrant une performance opérationnelle mixte et une activité du bilan.
Zola les revenus cumulés de l'année à ce jour ont augmenté de 26% grâce à une distribution accrue ; les revenus du troisième trimestre sont restés stables en glissement annuel. Les marges bénéficiaires brutes ont dépassé 30% pour le 11e trimestre consécutif. La trésorerie a diminué de $257K à $1.1M. La société a reconnu une perte de crédit de $4.7M liée à une note promissoire en cours et a reçu environ 2.7M d'actions d'Above Food Ingredients en paiement partiel.
Arcadia Biosciences (Nasdaq: RKDA) berichtete am 7. November 2025 über die Ergebnisse des dritten Quartals 2025 und verzeichnete eine gemischte operative Leistung und Bilanzaktivitäten.
Zola Umsatz seit Jahresbeginn bis heute stieg um 26% aufgrund erhöhter Vertriebskanäle; die Umsätze im dritten Quartal blieben im Jahresvergleich unverändert. Die Bruttomarge überschritt 30% im elften aufeinanderfolgenden Quartal. Der Cash-Bestand sank um $257K auf $1.1M. Das Unternehmen wies einen $4.7M Kreditverlust aufgrund einer ausstehenden Schuldverschreibung aus und erhielt ca. 2.7M Anteile von Above Food Ingredients als Teilrückzahlung.
Arcadia Biosciences (Nasdaq: RKDA) أبلغت عن نتائج الربع الثالث من عام 2025 في 7 نوفمبر 2025، مع أداء تشغيلي متنوع ونشاط في الميزانية.
Zola الإيرادات من بداية السنة وحتى التاريخ ارتفعت بنسبة 26% بفضل زيادة التوزيع؛ كانت إيرادات الربع الثالث ثابتة مقارنة بالعام السابق. تجاوزت هوامش الربح الإجمالي 30% لمدة الربع الحادي عشر على التوالي. انخفض النقد بمقدار $257K إلى $1.1M. اعترفت الشركة بـ $4.7M خسارة ائتمانية مرتبطة بمذكرة Promissory معتمدة وتلقت حوالي 2.7M سهماً من Above Food Ingredients كدفعة جزئية.
- Zola year-to-date revenue +26% through Sept 30, 2025
- Gross profit margins >30% for 11 consecutive quarters
- SG&A reduced by $671K in Q3 2025 versus Q3 2024
- Recognized $4.7M credit loss on outstanding promissory note
- Total revenues down $235K (15%) in Q3 2025 versus Q3 2024
- Cash balance declined $257K to $1.1M as of Sept 30, 2025
Insights
Quarterly results show operational stability with mixed balance-sheet noise; overall impact is neutral.
Arcadia recorded steady core performance: Zola year-to-date revenues grew
Material offsets create uncertainty: the company recognized a
Watch near-term balance-sheet and transaction milestones closely: resolution or payment under the Above Food note and the issuance/settlement of the remaining ~800,000 ABVE shares will materially affect reported receivables and equity values; the Roosevelt Resources business combination and any changes to the Form S-4 timeline will also drive near-term outcomes. Expect updates within typical SEC filing and transaction disclosure timeframes, notably subsequent SEC filings or disclosures to clarify the promissory note status and merger timing.
-- Zola® year-to-date revenues increase
-- Arcadia gross profit margins exceed
-- Arcadia cash balance declines by only
DALLAS, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the third quarter of 2025.
“We are very pleased with our performance for the third quarter of 2025.” said T.J. Schaefer, CEO of Arcadia. “Zola® coconut water revenues were flat year-over-year in the third quarter as we overlapped the initial sell-in to Zola’s largest customer during the third quarter of 2024. However, on a year-to-date basis, Zola coconut water revenues have grown
“In addition to our strong operating performance, we continue to own 2.7 million shares of Above Food Ingredients Inc. stock as a partial repayment of the
“Our pending business combination with Roosevelt Resources is still in progress,” Schaefer continued, “but uncertainty exists regarding the timing due to several factors including the ongoing federal government shutdown that went into effect over a month ago. We continue to monitor events closely, but the shutdown is obviously a situation that is outside of our control.”
Arcadia Biosciences, Inc.
Financial Snapshot
(Unaudited)
($ in thousands)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||
| 2025 | 2024 | Favorable/ (Unfavorable) | 2025 | 2024 | Favorable/ (Unfavorable) | ||||||||||||
| $ | % | $ | % | ||||||||||||||
| Total revenues | 1,302 | 1,537 | (235 | ) | (15 | %) | 3,957 | 3,829 | 128 | 3 | % | ||||||
| Total operating expenses | 2,454 | 3,297 | 843 | 26 | % | 5,082 | 5,198 | 116 | 2 | % | |||||||
| (Loss) income from continuing operations | (1,152 | ) | (1,760 | ) | 608 | 35 | % | (1,125 | ) | (1,369 | ) | 244 | 18 | % | |||
| Net (loss) income attributable to common stockholders | 856 | (1,612 | ) | 2,468 | 153 | % | (1,003 | ) | (2,974 | ) | 1,971 | 66 | % | ||||
Certain previously reported financial information has been reclassified to conform to the current year presentation. Reclassifications are related to the presentation of the financial results of our former GoodWheatTM brand as discontinued operations. The financial information above and narrative that follows relate to continuing operations unless stated otherwise.
More detailed financial information is included in the company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC), available in the Investors section of the company’s website under SEC Filings.
Revenues
Revenues decreased
Revenues increased
Operating Expenses
Cost of revenues decreased
Cost of revenues increased by
SG&A decreased by
Other operating expenses (income) increased by
Credit Loss and Common Stock Received
On May 1, 2025, Arcadia delivered a notice to Above Food Corp. to exercise a stock election option provided for in the Above Food Promissory Note related to the sale of GoodWheat assets in May 2024. The notice indicated that pursuant to the provisions of the Promissory Note, the number of shares issuable was approximately 3.5 million shares of common stock of Above Food Ingredients Inc. (ABVE), satisfying the final
Additionally, the first payment of principal and accrued interest under the Promissory Note was due on May 14, 2025, and as of September 30, 2025, had not been paid. As such, Arcadia recognized a credit loss of
Net Income / Loss Attributable to Common Stockholders
Net income attributable to common stockholders for the third quarter of 2025 was
Net loss attributable to common stockholders for the first nine months of 2025 was
Conference Call
In light of the ongoing transaction with Roosevelt Resources and the related registration statement on Form S-4 (initially filed with the SEC on February 14, 2025, and amended July 31, 2025), the company will not hold a conference call to discuss third quarter results.
About Arcadia Biosciences, Inc.
Since 2002, Arcadia Biosciences (Nasdaq: RKDA) has been innovating high-value, healthy ingredients to meet consumer demands for healthier choices. With its roots in agricultural innovation, Arcadia cultivates next-generation wellness products. For more information, visit www.arcadiabio.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about the company and its products, including statements relating to the company’s growth, cash position, operating costs, financial performance, commercialization of products, strategic transactions, our ability to obtain sufficient funding required to continue our operations and planned activities, our ability to obtain the stockholder approvals required to complete the proposed business combination transaction with Roosevelt Resources, LP and to satisfy the closing conditions contained in the agreements relating to the transaction, the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the proposed business combination transaction, and the anticipated timing of the closing of the proposed business combination transaction with Roosevelt Resources. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to, the risks set forth in filings that the company makes with the Securities and Exchange Commission from time to time, including in Arcadia’s Annual Report on Form 10-K for the year ended December 31, 2024 as amended, the registration statement on Form S-4 initially filed with the SEC on February 14, 2025 and amended July 31, 2025, and other filings that the company makes with the SEC. These forward-looking statements speak only as of the date hereof, and except as required by law, Arcadia Biosciences, Inc. disclaims any obligation to update these forward-looking statements.
No Offer or Solicitation
As previously reported on a Report on Form 8-K filed by the company with the SEC, on December 4, 2024, the company, Roosevelt Resources, LP, a Texas limited partnership, and certain other parties entered into a Securities Exchange Agreement (as the same may be amended, the Exchange Agreement) providing for the combination of the two companies in an all-stock transaction. Under the terms of the Exchange Agreement, at the closing of the transactions contemplated by the Exchange Agreement, Arcadia will issue to the partners of Roosevelt shares of Arcadia common stock in exchange for all of the equity interests in Roosevelt.
This press release, including the information contained herein, is not intended to and does not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or in respect of the proposed transaction or (ii) an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended, or an exemption therefrom.
Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, no offer will be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.
Additional Information for Stockholders
In connection with the proposed transaction, Arcadia intends to file relevant materials with the SEC and previously filed a Registration Statement on Form S-4 that includes a preliminary proxy statement/prospectus, with the SEC on February 14, 2025, and filed a pre-effective amendment to the Registration Statement on July 31, 2025. After the Registration Statement is declared effective by the SEC, Arcadia intends to mail a definitive proxy statement/prospectus to the stockholders of Arcadia relating to a meeting of stockholders to consider matters relating to the proposed transaction and other matters. This press release is not a substitute for the proxy statement/ prospectus or the Registration Statement or for any other document that Arcadia may file with the SEC and send to Arcadia’s stockholders in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS OF ARCADIA ARE URGED TO CAREFULLY AND THOROUGHLY READ THE REGISTRATION STATEMENT AND THE PROXY STATEMENT/PROSPECTUS, AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND OTHER RELEVANT DOCUMENTS FILED BY ARCADIA WITH THE SEC, WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ARCADIA, ROOSEVELT, THE PROPOSED TRANSACTION, THE RISKS RELATED THERETO AND RELATED MATTERS.
Investors will be able to obtain free copies of the Registration Statement and proxy statement/prospectus, as each may be amended from time to time, and other relevant documents filed by Arcadia with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. Copies of documents filed with the SEC by Arcadia will be available free of charge from Arcadia’s website at www.arcadiabio.com under the “Investors” tab. In addition, investors and stockholders should note that Arcadia communicates with investors and the public using its website. Stockholders are urged to read the proxy statement/prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed transactions.
Participants in the Proxy Solicitation
Arcadia, Roosevelt and their respective directors, partners and certain of their officers and other members of management and employees may be deemed, under SEC rules, to be participants in the solicitation of proxies from Arcadia’s stockholders in connection with the proposed transactions. Information regarding the officers and directors of Arcadia is included in Arcadia’s most recent Annual Report on Form 10-K, as amended, filed with the SEC, including any information incorporated therein by reference, its definitive proxy statement for its 2024 annual meeting filed with the SEC on May 16, 2024, and in the Registration Statement initially filed with the SEC on February 14, 2025 and as amended July 31, 2025, and any amendments thereto as filed with the SEC. Additional information regarding such persons, as well as information regarding Roosevelt’s directors, managers and officers and other persons who may be deemed participants in the proposed transaction, will be set forth in the Registration Statement and proxy statement/prospectus, and any amendments thereto, and other materials, when they are filed with the SEC in connection with the proposed transaction. Free copies of these documents may be obtained from the sources indicated above.
Arcadia Biosciences Contact:
T.J. Schaefer
ir@arcadiabio.com
FAQ
What were Arcadia Biosciences (RKDA) total revenues for Q3 2025?
How much did Zola coconut water sales grow for Arcadia (RKDA) year-to-date 2025?
What credit loss did Arcadia (RKDA) record related to Above Food in 2025?
How many Above Food Ingredients shares does Arcadia (RKDA) hold after the stock election?
What was Arcadia’s net income attributable to common stockholders in Q3 2025?
Did Arcadia (RKDA) host a conference call for Q3 2025 results?
